Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Barnes TR, Paton C, Cavanagh MR, Hancock E, Taylor DM; UK Prescribing Observatory for Mental Health.

Schizophr Bull. 2007 Nov;33(6):1397-403. Epub 2007 May 4.

2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
3.

Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK.

Barnes TR, Bhatti SF, Adroer R, Paton C.

BMJ Open. 2015 Oct 1;5(10):e007633. doi: 10.1136/bmjopen-2015-007633.

4.

Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme.

Barnes TR, Paton C, Hancock E, Cavanagh MR, Taylor D, Lelliott P; UK Prescribing Observatory for Mental Health.

Acta Psychiatr Scand. 2008 Jul;118(1):26-33. doi: 10.1111/j.1600-0447.2008.01203.x.

PMID:
18582345
5.

Metabolic monitoring for patients treated with antipsychotic medications.

Cohn TA, Sernyak MJ.

Can J Psychiatry. 2006 Jul;51(8):492-501. Review.

PMID:
16933586
6.

POMHS 9b - antipsychotic prescribing in people with a learning disability.

Thalitaya MD, Udu V, Nicholls M, Clark T, Prasher VP.

Psychiatr Danub. 2011 Sep;23 Suppl 1:S50-6.

PMID:
21894103
7.

The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.

Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M.

Int Clin Psychopharmacol. 2011 Nov;26(6):291-302. doi: 10.1097/YIC.0b013e32834a5bf6.

PMID:
21876442
8.

Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.

Pallava A, Chadda RK, Sood M, Lakshmy R.

Nord J Psychiatry. 2012 Jun;66(3):215-21. doi: 10.3109/08039488.2011.621977. Epub 2011 Oct 24.

PMID:
22017264
9.
10.

Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM.

JAMA Psychiatry. 2014 Dec 1;71(12):1350-63. doi: 10.1001/jamapsychiatry.2014.1314.

PMID:
25321337
11.

Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.

Moeller KE, Rigler SK, Mayorga A, Nazir N, Shireman TI.

Schizophr Res. 2011 Mar;126(1-3):117-23. doi: 10.1016/j.schres.2010.11.015. Epub 2010 Dec 18.

PMID:
21168994
12.

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.

Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, Fonseca V, Winstead D.

BMC Psychiatry. 2009 Dec 18;9:80. doi: 10.1186/1471-244X-9-80.

13.

Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs.

Laugharne J, Waterreus AJ, Castle DJ, Dragovic M.

Australas Psychiatry. 2016 Feb;24(1):62-6. doi: 10.1177/1039856215618521. Epub 2015 Dec 3.

PMID:
26635377
14.

Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.

Schneiderhan ME, Batscha CL, Rosen C.

Pharmacotherapy. 2009 Aug;29(8):975-87. doi: 10.1592/phco.29.8.975.

PMID:
19637951
15.

A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.

Kelly AC, Sheitman BB, Hamer RM, Rhyne DC, Reed RM, Graham KA, Rau SW, Gilmore JH, Perkins DO, Peebles SS, VanderZwaag CJ, Jarskog LF.

J Clin Psychopharmacol. 2014 Aug;34(4):441-5. doi: 10.1097/JCP.0000000000000159.

PMID:
24943389
16.

Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications.

Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, Saint-Vil R, Kane JM, Manu P.

Am J Psychiatry. 2005 Jun;162(6):1217-21.

PMID:
15930076
17.

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M.

Psychol Med. 2012 Jan;42(1):125-47. doi: 10.1017/S003329171100105X. Epub 2011 Aug 10. Review.

PMID:
21846426
18.

Physical health of patients with severe mental illness: an intervention on medium secure forensic unit.

Vasudev K, Thakkar PB, Mitcheson N.

Int J Health Care Qual Assur. 2012;25(4):363-70.

PMID:
22755485
19.

[Schizophrenia, diabetes mellitus and antipsychotics].

Gury C.

Encephale. 2004 Jul-Aug;30(4):382-91. Review. French.

PMID:
15538314
20.

An evaluation of monitoring practices in patients on second generation antipsychotics.

Nguyen D, Brakoulias V, Boyce P.

Australas Psychiatry. 2009 Aug;17(4):295-9. doi: 10.1080/10398560902842519.

PMID:
19585292

Supplemental Content

Support Center